The goal of this webinar is to discuss the evolution of the role of imaging in the assessment of lymphomatous disease. The focus will be on the recently implemented Lugano criteria. The incorporation of the Lugano 2014 Criteria for the assessment of lymphoma patients’ response to therapy represents an important paradigm shift in the initial and on-study imaging evaluations. The dominant changes in the Lugano criteria involve the use of FDG-PET imaging along with the conventional CT assessment of lymphoma patients. The strengths and pitfalls along with the importance of the proper selection of representative disease will be discussed in detail. In addition, this webinar will address evolving issues regarding the use of immunoncologic drugs and their effect on the individual patient images and outcome. In particular, the concept of pseudoprogression and its manifestations on CT and FDG-PET imaging will be elucidated along with a discussion of solutions to this confounding challenge.
This presentation will include a detailed discussion of a number of workflow paradigms for the implementation of the Lugano 2014 assessment in oncology clinical trials. This discussion will also include the use of PET/CT quantitative measurements and the five point scale along with the validation of these approaches to further objectify reader interpretation. The components highlighted in the proposed workflow and discussion points in this webinar are intended to help achieve more uniform and consistent multi-time point imaging assessments in lymphoma clinical trials.
This webinar will explore:
- Workflow paradigms for implementation of the Lugano 2014 assessment in oncology trials
- Evolving issues regarding the use of immunoncologic drugs and their effect on the individual patient images and outcome
- Usage of PET/CT quantitative measurements and the five point scale along with the validations of these approaches to further objectify reader interpretation
- How to achieve more uniform and consistent multi-time point imaging assessments in lymphoma clinical trials
Ronald Van Heertum, MD, Vice President, Medical Affairs, Oncologic and Molecular Imaging, Bioclinica
Ronald L. Van Heertum is Vice President of Oncologic and Molecular Imaging at Bioclinica. He is responsible for the management and implementation of all aspects of Molecular Imaging. Prior to coming to Bioclinica, Dr. Van Heertum was Professor and Executive Vice Chairman/CAO, Department of Radiology at Columbia University College of Physicians & Surgeons as well as Director of Nuclear Medicine and PET. In this position he participated in many clinical trials in oncology, neurology and psychiatry and established an international reputation in SPECT and PET imaging. He has authored or co-authored over 250 publications and is the editor of a book on Brain Imaging that is now in its 4th Edition. He has been an active member of the RSNA, American College of Radiology where he is an FACR, a life member and former Chairman of the American Board of Nuclear Medicine and the Society of Nuclear Medicine and is listed in Who’s Who in America, Who’s Who in Medicine and Healthcare and The Best Doctors in America.
Robert Scarimbolo, Director, Director, Medical Affairs, Oncologic and Molecular Imaging, Bioclinica
Robert Scarimbolo is a Director of Medical Affairs at Bioclinica. He is responsible for developing processes to support and manage PET/CT oncology trials, including training paradigms and image software analysis methods. He began his career at Bioclinica in 2007 and has held numerous roles of increasing responsibility within the Global Clinical Operations and Medical Affairs departments. Robert earned his BSc in Health Sciences from Stony Brook University in New York.
Zachary LaVoie, Manager, Medical Affairs, Oncologic and Molecular Imaging, Bioclinica
Zachary LaVoie is a Manager of Medical Affairs at Bioclinica. He is primarily responsible for analyzing sponsor protocols and defining reading criteria, read design and workflow. Additional responsibilities include devising processes to support and manage imaging projects, including image analysis software validation and enhancement. He began his career at Bioclinica (formerly CoreLab Partners) in 2011 as a Clinical Project Coordinator and has held numerous roles of increasing responsibility within Clinical Project Management. Prior to making the move to Medical Affairs within Bioclinica, Zachary held the position of Clinical Project Manager. Within this role, he was responsible for managing over 20 Global Phase I-III studies across multiple indications and response criteria. Zachary earned his BA in Biology from McDaniel College in Maryland.
Who Should Attend?
- Clinical Project Management
- Clinical Trial Study/Protocol Managers
- Medical Monitors
- Imaging Leads
- Medical Oncologists
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging and Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, Bioclinica offers a network of research sites, patient recruitment-retention solutions, and a post-approval research division.